Latest Medical Services News

4DMedical has secured a pivotal three-year contract with SimonMed Imaging to deploy its CT:VQ™ lung imaging technology across over 170 US outpatient centres, while FY26 revenue rose 23% to $7.2 million on record scan volumes and global expansion.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Third Age Health Services Limited lifted revenue by 18% to NZD 22.49 million in FY26, driven by acquisitions and aged care growth, while net profit after tax rose 25% to NZD 3.09 million.

4DMedical has cleared a major regulatory hurdle with the Therapeutic Goods Administration approving its CT:VQ™ lung imaging software, paving the way for commercial use across Australia and strengthening its global footprint.

Green Cross Health Limited reported a 28% rise in net profit to NZD 20.4 million for FY26, driven by gains in both pharmacy and medical divisions. The company announced a conditional sale of its Medical division to Tend Health for NZD 270 million, aiming to refocus on its core pharmacy business.

Green Cross Health lifted net profit by 28% to NZD 20.4 million in FY26, driven by stronger medical funding and pharmacy revenue growth, while preparing to launch a new Primary Health Organisation.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

CONNEQT Health has disclosed significant revisions to its 2025 financial results, highlighting increased losses driven by a larger-than-expected fair value write-down on its inHealth investment and a heightened inventory provision.